• Viktoriia Vivcharuk Kharkiv National Medical University
Keywords: hemangioma, children, morphological type, apoptosis, involution, residual changes, treatment, hemangioma severity scale, hemangioma activity scale, visual analogue scale, sFas, sFasL


The article discusses analysis of examinations and treatment results 100 children with hemangiomas different localizations on the different stages of existence. The study included patients of different ages, from birth to 6 years. Importance of primary assessment of severity and activity of hemangioma`s, for the choice of treatment, was considered. Correlation between clinical course of hemangiomas and soluble Fas/FasL was analyzed.

The object of the research: Clinical course of hemangiomas of different morphological types, soluble form of Fas and FasL in the serum of patients with hemangiomas.

Investigated problem: Improving the results of treatment of hemangiomas in children.

The main scientific results: Predicting the course of hemangiomas in children allows to determine the need for treatment at different stages of their existence, as well as to carry out timely correction of the prescribed treatment to achieve good cosmetic and functional results.

The area of practical use of the research results: Department of Pediatrics, Pediatric Surgery, Dermatology.

Innovative technological product: Defined characteristics will help in predicting the course of hemangiomas and the effectiveness of their treatment.

Scope of the innovative technological product: Clinical pediatric practice.


Download data is not yet available.

Author Biography

Viktoriia Vivcharuk, Kharkiv National Medical University

Department of Pediatric Surgery and Pediatric Anesthesiology


Bota, M., Popa, G., Blag, C., Tataru, A. (2015). Infantile hemangioma: a brief review. Medicine and Pharmacy Reports, 88 (1), 23–27. doi: DOI:

International Society for the Study of Vascular Anomalies (2018). ISSVA classification of vascular anomalies.

Mulligan, P. R., Prajapati, H. J. S., Martin, L. G., Patel, T. H. (2014). Vascular anomalies: classification, imaging characteristics and implications for interventional radiology treatment approaches. The British Journal of Radiology, 87 (1035), 20130392. doi: DOI:

Püttgen, K. B. (2014). Diagnosis and Management of Infantile Hemangiomas. Pediatric Clinics of North America, 61 (2), 383–402. doi: DOI:

Rotter, A., de Oliveira, Z. N. P. (2017). Infantile hemangioma: pathogenesis and mechanisms of action of propranolol. JDDG: Journal Der Deutschen Dermatologischen Gesellschaft, 15 (12), 1185–1190. doi: DOI:

Yu, Y., Fuhr, J., Boye, E., Gyorffy, S., Soker, S., Atala, A. et. al. (2006). Mesenchymal Stem Cells and Adipogenesis in Hemangioma Involution. STEM CELLS, 24 (6), 1605–1612. doi: DOI:

Lee, J. W., Chung, H. Y. (2018). Vascular anomalies of the head and neck: current overview. Archives of Craniofacial Surgery, 19 (4), 243–247. doi: DOI:

Luu, M., Frieden, I. J. (2013). Haemangioma: clinical course, complications and management. British Journal of Dermatology, 169 (1), 20–30. doi: DOI:

Léauté-Labrèze, C., Harper, J. I., Hoeger, P. H. (2017). Infantile haemangioma. The Lancet, 390 (10089), 85–94. doi: DOI:

Boscolo, E., Bischoff, J. (2009). Vasculogenesis in infantile hemangioma. Angiogenesis, 12 (2), 197–207. doi: DOI:

Ji, Y., Wang, Q., Chen, S., Xiang, B., Xu, Z., Li, Y. et. al. (2016). Oral atenolol therapy for proliferating infantile hemangioma. Medicine, 95 (24), e3908. doi: DOI:

Garzon, M. C., Epstein, L. G., Heyer, G. L., Frommelt, P. C., Orbach, D. B., Baylis, A. L. et. al. (2016). PHACE Syndrome: Consensus-Derived Diagnosis and Care Recommendations. The Journal of Pediatrics, 178, 24–33.e2. doi: DOI:

Gontijo, B. (2014). Complications of infantile hemangiomas. Clinics in Dermatology, 32 (4), 471–476. doi: DOI:

Satterfield, K. R., Chambers, C. B. (2019). Current treatment and management of infantile hemangiomas. Survey of Ophthalmology, 64 (5), 608–618. doi: DOI:

Darrow, D. H., Greene, A. K., Mancini, A. J., Nopper, A. J. (2015). Diagnosis and Management of Infantile Hemangioma. Pediatrics, 136 (4), e1060–e1104. doi: DOI:

Pu ttgen, K., Lucky, A., Adams, D., Pope, E., McCuaig, C. et. al. (2016). Topical Timolol Maleate Treatment of Infantile Hemangiomas. Pediatrics, 138 (3), e20160355. doi: DOI:

Zhang, L., Yuan, W.-E., Zheng, J.-W. (2016). Pharmacological therapies for infantile hemangiomas: A clinical study in 853 consecutive patients using a standard treatment algorithm. Scientific Reports, 6 (1). doi: DOI:

Koka, K., Mukherjee, B., Agarkar, S. (2018). Effect of oral propranolol on periocular Capillary Hemangiomas of Infancy. Pediatrics & Neonatology, 59 (4), 390–396. doi: DOI:

Leaute-Labreze, C., Boccara, O., Degrugillier-Chopinet, C., Mazereeuw-Hautier, J., Prey, S., Lebbe, G. et. al. (2016). Safety of Oral Propranolol for the Treatment of Infantile Hemangioma: A Systematic Review. Pediatrics, 138 (4), e20160353. doi: DOI:

Harter, N., Mancini, A. J. (2019). Diagnosis and Management of Infantile Hemangiomas in the Neonate. Pediatric Clinics of North America, 66 (2), 437–459. doi: DOI:

Chen, Z.-Y., Wang, Q.-N., Zhu, Y.-H., Zhou, L.-Y., Xu, T., He, Z.-Y., Yang, Y. (2019). Progress in the treatment of infantile hemangioma. Annals of Translational Medicine, 7 (22), 692–692. doi: DOI:

Berkman, N. D., Brownley, K. A., Peat, C. M., Cullen, K. E. (2015). Evidence-based practice center systematic review protocol. Project title: Management and outcomes of binge eating disorder (BED).

Grzesik, P., Wu, J. (2017). Current perspectives on the optimal management of infantile hemangioma. Pediatric Health, Medicine and Therapeutics, 8, 107–116. doi: DOI:

Moyakine, A. V., Herwegen, B., van der Vleuten, C. J. M. (2017). Use of the Hemangioma Severity Scale to facilitate treatment decisions for infantile hemangiomas. Journal of the American Academy of Dermatology, 77 (5), 868–873. doi: DOI:

Smith, C. J. F., Friedlander, S. F., Guma, M., Kavanaugh, A., Chambers, C. D. (2017). Infantile Hemangiomas: An Updated Review on Risk Factors, Pathogenesis, and Treatment. Birth Defects Research, 109 (11), 809–815. doi: DOI:

Razon, M. J., Kraeling, B. M., Mulliken, J. B., Bischoff, J. (1998). Increased Apoptosis Coincides with Onset of Involution in Infantile Hemangioma. Microcirculation, 5 (2‐3), 189–195. doi: DOI:

Xia, P., Gamble, J. R., Rye, K.-A., Wang, L., Hii, C. S. T., Cockerill, P. et. al. (1998). Tumor necrosis factor- induces adhesion molecule expression through the sphingosine kinase pathway. Proceedings of the National Academy of Sciences, 95 (24), 14196–14201. doi: DOI:

Musiał, K., Zwolińska, D. (2011). Matrix metalloproteinases and soluble Fas/FasL system as novel regulators of apoptosis in children and young adults on chronic dialysis. Apoptosis, 16 (7), 653–659. doi: DOI:

Adly, A. A., Ismail, E. A., Andrawes, N. G., Mahmoud, M. M., Eladawy, R. (2016). Soluble Fas/FasL ratio as a marker of vasculopathy in children and adolescents with sickle cell disease. Cytokine, 79, 52–58. doi: DOI:

Luo, J., Wang, Y., Yu, B., Qian, H., He, Y., Shi, G. (2017). A Potential of sFasL in Preventing Gland Injury in Sjogren’s Syndrome. BioMed Research International, 2017, 1–6. doi: DOI:

Yamada, A., Arakaki, R., Saito, M., Kudo, Y., Ishimaru, N. (2017). Dual Role of Fas/FasL-Mediated Signal in Peripheral Immune Tolerance. Frontiers in Immunology, 8. doi: DOI:

Izawa, T., Arakaki, R., Ishimaru, N. (2017). Role of Fas and RANKL Signaling in Peripheral Immune Tolerance. Journal of Clinical & Cellular Immunology, 8 (4). doi: DOI:

Kosacka, M., Porębska, I., Korzeniewska, A., Rubinsztajn, R., Grabicki, M., Jankowska, R. et. al. (2016). Serum levels of apoptosis-related markers (sFasL, TNF-a, p53 and bcl-2) in COPD patients. Pneumonologia i Alergologia Polska, 84 (1), 11–15. doi: DOI:

Zheng, J. W., Zhang, L., Zhou, Q., Mai, H. M., Wang, Y. A., Fan, X. D. et. al. (2013). A practical guide to treatment of infantile hemangiomas of the head and neck. International journal of clinical and experimental medicine, 6 (10), 851–860.

Krowchuk, D. P., Frieden, I. J., Mancini, A. J., Darrow, D. H., Blei, F. et. al. (2018). Clinical Practice Guideline for the Management of Infantile Hemangiomas. Pediatrics, 143 (1), e20183475. doi: DOI:

Wu, H. W., Liu, C., Wang, X., Zhang, L., Yuan, W., Zheng, J. W. et. al. (2017). Topical Application of 0.5 % Timolol Maleate Hydrogel for the Treatment of Superficial Infantile Hemangioma. Frontiers in Oncology, 7. doi: DOI:

Marey, H. M., Elmazar, H. F., Mandour, S. S., Khairy, H. A. (2017). Combined Oral and Topical Beta Blockers for the Treatment of Early Proliferative Superficial Periocular Infantile Capillary Hemangioma. Journal of Pediatric Ophthalmology & Strabismus, 55 (1), 37–42. doi: DOI:

Dou, T. M. (2017). The evaluation value of the quantitative electroencephalogram for the prognosis of neonatal hypoxic ischemic encephalopathy and its relationship with serological indicators. Journal of Hainan Medical University, 23 (11), 120–123.

Fathi, M., Amirghofran, Z., Shahriari, M. (2011). Soluble Fas and Fas ligand and prognosis in children with acute lymphoblastic leukemia. Medical Oncology, 29 (3), 2046–2052. doi: DOI:

Xing, X., Ouyang, T. X., Yuan, S. M. et. al. (2006) The expression and role of Fas/FasL in infantile hemangioma. Chinese Journal of Plastic Surgery, 22 (2), 116–120.

👁 96
⬇ 94
How to Cite
Innovative technologies in healthcare